OBJECTIVE: To ascertain progression and regression of cervical dysplasia in HIV-infected women in Soweto. DESIGN: Prospective cohort. METHODS: Women attending an HIV wellness clinic were offered cervical smears as part of care; smears were assessed using the Bethesda system. Those with high-grade lesions or worse were referred for colposcopy. Progression analyses included women with at least two smears at least 5.5 months apart. Hazard ratios were used to ascertain predictors of progression. RESULTS: Two thousand, three hundred and twenty-five women had a baseline smear; their median age and CD4 cell count was 32 years and 312 cells/μl, respectively; 17% were taking highly active antiretroviral therapy (HAART); 62, 20 and 14% had normal, low-grade squamous intraepithelial lesions (LSIL) or high-grade squamous intraepithelial lesions (HSIL), respectively. Of those with baseline normal or LSIL smears, 1074 had another smear; progression from normal to LSIL was 9.6/100 person-years (95% CI 8.3-11.1) and progression from normal or LSIL to HSIL was 4.6/100 person-years (95% CI 3.9-5.5). Of 225 women with LSIL at baseline and at least one subsequent smear at least 11.5 months later, 44.0% regressed to normal (21.2/100 person-years (95% CI 17.5-25.7)). Multivariate models suggested increasing risk for progression in women with CD4 cell count below 500 cells/μl and HAART may reduce the risk of progression [adjusted hazard ratio (aHR) 0.72 (0.52-0.99)]. CONCLUSION: HIV-infected women have high rates of prevalent and incident HSIL and LSIL with relatively low risk of regression to normal from LSIL. HAART appears to protect against progression. Our findings suggest cervical screening intervals should be less than 10 years - irrespective of age in women with CD4 cell counts below 500 cells/μl.
OBJECTIVE: To ascertain progression and regression of cervical dysplasia in HIV-infectedwomen in Soweto. DESIGN: Prospective cohort. METHODS:Women attending an HIV wellness clinic were offered cervical smears as part of care; smears were assessed using the Bethesda system. Those with high-grade lesions or worse were referred for colposcopy. Progression analyses included women with at least two smears at least 5.5 months apart. Hazard ratios were used to ascertain predictors of progression. RESULTS: Two thousand, three hundred and twenty-five women had a baseline smear; their median age and CD4 cell count was 32 years and 312 cells/μl, respectively; 17% were taking highly active antiretroviral therapy (HAART); 62, 20 and 14% had normal, low-grade squamous intraepithelial lesions (LSIL) or high-grade squamous intraepithelial lesions (HSIL), respectively. Of those with baseline normal or LSIL smears, 1074 had another smear; progression from normal to LSIL was 9.6/100 person-years (95% CI 8.3-11.1) and progression from normal or LSIL to HSIL was 4.6/100 person-years (95% CI 3.9-5.5). Of 225 women with LSIL at baseline and at least one subsequent smear at least 11.5 months later, 44.0% regressed to normal (21.2/100 person-years (95% CI 17.5-25.7)). Multivariate models suggested increasing risk for progression in women with CD4 cell count below 500 cells/μl and HAART may reduce the risk of progression [adjusted hazard ratio (aHR) 0.72 (0.52-0.99)]. CONCLUSION:HIV-infectedwomen have high rates of prevalent and incident HSIL and LSIL with relatively low risk of regression to normal from LSIL. HAART appears to protect against progression. Our findings suggest cervical screening intervals should be less than 10 years - irrespective of age in women with CD4 cell counts below 500 cells/μl.
Authors: H Minkoff; L Ahdieh; L S Massad; K Anastos; D H Watts; S Melnick; L Muderspach; R Burk; J Palefsky Journal: AIDS Date: 2001-11-09 Impact factor: 4.177
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: S Fonn; B Bloch; M Mabina; S Carpenter; H Cronje; C Maise; M Bennun; G du Toit; E de Jonge; I Manana; G Lindeque Journal: S Afr Med J Date: 2002-02
Authors: N Muñoz; F X Bosch; S de Sanjosé; L Tafur; I Izarzugaza; M Gili; P Viladiu; C Navarro; C Martos; N Ascunce Journal: Int J Cancer Date: 1992-11-11 Impact factor: 7.396
Authors: Sanghyuk S Shin; Catherine L Carpenter; Maria L Ekstrand; Qiao Wang; Surbhi Grover; Nicola M Zetola; Kartik Yadav; Sanjeev Sinha; Adeline M Nyamathi Journal: Int J STD AIDS Date: 2019-02-27 Impact factor: 1.359
Authors: Daniel Westreich; Naiomi Jamal; Jennifer S Smith; Doreen Schulze; Sophie Williams; Pam Michelow; Simon Levin; Cynthia Firnhaber Journal: Contraception Date: 2014-01-07 Impact factor: 3.375
Authors: Heather L White; Chishimba Mulambia; Moses Sinkala; Mulindi H Mwanahamuntu; Groesbeck P Parham; Linda Moneyham; Diane M Grimley; Eric Chamot Journal: Soc Sci Med Date: 2012-03-07 Impact factor: 4.634
Authors: David H Adler; Lisa Kakinami; Tebogo Modisenyane; Nkeko Tshabangu; Lerato Mohapi; Guy De Bruyn; Neil A Martinson; Tanvier Omar Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Sarah M Lofgren; Talaat Tadros; Gina Herring-Bailey; George Birdsong; Marina Mosunjac; Lisa Flowers; Minh Ly Nguyen Journal: AIDS Res Hum Retroviruses Date: 2015-03-19 Impact factor: 2.205